Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternate Day Buprenorphine Administration Phase XII
NCT00000235Phase 2
Key facts
- Status
- Completed
- Countries
- 1
- Sponsor
- National Institute on Drug Abuse
- Modality
- Orthosteric Ligands
- Drugs
- buprenorphine
- Conditions
- opioid use disorder (OUD)
01
Overview
Phase 2, randomised, double-blind trial of buprenorphine in opioid use disorder (OUD) (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Drug use, Opioid withdrawal and 2 more. Status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
120-hour Dosing
Buprenorphine administered every 120 hours (6x daily dose)
Daily Dosing
Buprenorphine administered daily (1x daily dose)
03
Who it enrols
Adult patients with opioid-related disorders.
04
Endpoints
Primary
Drug use
Opioid withdrawal
Opioid agonist effects
Dose choice
Beyond the preview
Go deeper on NCT00000235.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000235.